FDA Times Patent Clock for Life-Saving Pulmonary Valve
Published Date: 6/25/2025
Notice
Summary
The FDA has officially set the review period for the EDWARDS SAPIEN 3 Transcatheter Pulmonary Valve, helping the company extend its patent protection. This means the makers get more time to keep their invention exclusive, which can impact when generic versions hit the market. Patients and competitors should watch for these changes as they affect device availability and innovation timing.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Manufacturer Can Seek Patent Extension
The FDA has determined the regulatory review period for the EDWARDS SAPIEN 3 Transcatheter Pulmonary Valve, which lets the manufacturer submit an application to the U.S. Patent and Trademark Office to extend its patent protection. This gives the company more time to keep the device exclusive before competitors can sell similar products.
Potential Delay of Competing Devices
Because the FDA set the regulatory review period and the company can seek a patent extension, competing or generic versions of the EDWARDS SAPIEN 3 device may be delayed from entering the market. Patients and competitors should watch this change because it can affect device availability, competition, and the timing of lower-cost alternatives.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-11600, Request for Nominations for Voting Members on the Tobacco Products Scientific Advisory Committee
The FDA is looking for awesome experts and everyday folks to join the Tobacco Products Scientific Advisory Committee and help make smart decisions about tobacco products. They need 5 new members, including doctors, scientists, and a public representative, to bring fresh ideas and keep things safe. If you or someone you know fits the bill, now’s the time to apply and make a difference!
Next: 2025-11602, Determination of Regulatory Review Period for Purposes of Patent Extension; AGAMREE
The FDA has officially set the review period for AGAMREE, a human drug product, so its patent can be extended. This helps the company get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this timing update could impact your plans and profits.